The separation of this new tumor type from the poorly defined category of high grade non-ITACs is particularly relevant in view of the emerging opportunities for targeted treatments in SMARCB1 deficient tumors (see below for discussion). This evidence concerns the gene SMARCB1 and neoplasm.